Perioperative treatment and biomarker analysis of <scp>LP002</scp> , an <scp>anti‐PD‐L1</scp> antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer-Reference-Cited by-同舟云学术

Perioperative treatment and biomarker analysis of LP002 , an anti‐PD‐L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer

Published:2022-11-07 Issue:5 Volume:12 Page:5639-5648
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Tang Jia‐lin¹^ORCID,Zhang Bo¹,Xu Jian‐ping¹,Qi Ling¹,Xin Dao¹^ORCID,Wang Lin¹^ORCID,Wang Bing‐zhi²,Tian Yan‐tao³,Li Yong⁴,Huang Jing¹⁵^ORCID

Affiliation:

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Pathology and Resident Training Base, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

3. Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

4. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

5. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5414

Reference25 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

3. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

4. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

5. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review;Frontiers in Immunology;2024-01-30

2. CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1;Molecular Biotechnology;2023-04-13